NEJM 2023 Mayo Clinic: GLP-1 Agonists for Weight Loss Treatments related to this article Ready to talk through this with a provider
The primary endpoints were the percentage change in body weight relative to baseline and the proportion of patients achieving a weight loss of 5% or more ( 4.11 SURMOUNT-CN: tirzepatide for weight loss in Chinese obese and overweight adults The SURMOUNT-CN trial recruited 210 obese or overweight adult patients in China, who received weekly doses of tirzepatide (10 mg, 15 mg) or placebo for 52 weeks
They recognize that clinical trials showed modest effects (average 2.6 kg over 12 weeks in responders), appreciate that individual response varies significantly, commit to proper nutrition and exercise foundations, and accept that the peptide is used for research purposes under medical supervision
Zepbound Lawsuit 2026 Update July 1, 2026: Over 80 Lawsuits About Zepbound, Similar GLP-1 Drugs Join the MDL The consolidated multidistrict litigation about Zepbound and other GLP-1 products has grown to include 3,848 lawsuits as of July 1, 2026
While not 24/7, this clinical touchpoint goes beyond what some platforms offer
